SLC5A2 and chronic kidney disease: Therefore, we examined the effects of the SGLT2 inhibitor dapagliflozin on fluid status and hemodynamic parameters, including the antidiuretic hormone vasopressin and renin-angiotensin aldosterone system (RAAS), for 6 months in CKD patients with or without fluid retention.